233 related articles for article (PubMed ID: 26104032)
1. Pitavastatin therapy in polymedicated patients is associated with a low risk of drug-drug interactions: analysis of real-world and phase 3 clinical trial data.
Gosho M; Tanahashi M; Hounslow N; Teramoto T
Int J Clin Pharmacol Ther; 2015 Aug; 53(8):635-46. PubMed ID: 26104032
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?
Corsini A; Ceska R
Curr Med Res Opin; 2011 Aug; 27(8):1551-62. PubMed ID: 21682551
[TBL] [Abstract][Full Text] [Related]
3. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
da Silva PM
Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
[TBL] [Abstract][Full Text] [Related]
4. Pitavastatin: an overview.
Saito Y
Atheroscler Suppl; 2011 Nov; 12(3):271-6. PubMed ID: 22152281
[TBL] [Abstract][Full Text] [Related]
5. Pitavastatin - from clinical trials to clinical practice.
Masana L
Atheroscler Suppl; 2010 Dec; 11(3):15-22. PubMed ID: 21193154
[TBL] [Abstract][Full Text] [Related]
6. Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.
Barrios V; Escobar C; Zamorano JL
Expert Rev Cardiovasc Ther; 2013 Dec; 11(12):1597-612. PubMed ID: 24215190
[TBL] [Abstract][Full Text] [Related]
7. Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.
Catapano AL
Curr Vasc Pharmacol; 2012 Mar; 10(2):257-67. PubMed ID: 22022768
[TBL] [Abstract][Full Text] [Related]
8. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].
Yamazaki H; Fujino H; Kanazawa M; Tamaki T; Sato F; Suzuki M; Kitahara M
Nihon Yakurigaku Zasshi; 2004 May; 123(5):349-62. PubMed ID: 15118259
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
11. The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.
Teramoto T
Expert Opin Pharmacother; 2012 Apr; 13(6):859-65. PubMed ID: 22332608
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin: a new HMG-CoA reductase inhibitor.
Wensel TM; Waldrop BA; Wensel B
Ann Pharmacother; 2010 Mar; 44(3):507-14. PubMed ID: 20179258
[TBL] [Abstract][Full Text] [Related]
13. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals.
Saito Y
Vasc Health Risk Manag; 2009; 5():921-36. PubMed ID: 19997573
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin for the treatment of primary hyperlipidemia and mixed dyslipidemia.
Gotto AM; Moon J
Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1079-90. PubMed ID: 20670185
[TBL] [Abstract][Full Text] [Related]
15. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin.
Arnaboldi L; Corsini A
Atheroscler Suppl; 2015 Jan; 16():1-27. PubMed ID: 25575403
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.
Hu M; Tomlinson B
Expert Opin Drug Metab Toxicol; 2014 Jan; 10(1):51-65. PubMed ID: 24156555
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin (Livalo)--the seventh statin.
Med Lett Drugs Ther; 2010 Jul; 52(1343):57-8. PubMed ID: 20651638
[No Abstract] [Full Text] [Related]
18. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin.
Mukhtar RY; Reid J; Reckless JP
Int J Clin Pract; 2005 Feb; 59(2):239-52. PubMed ID: 15854203
[TBL] [Abstract][Full Text] [Related]
20. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
